tenofovir disoproxil
Selected indexed studies
- Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. (Lancet, 2020) [PMID:32711800]
- Tenofovir disoproxil fumarate. (Drugs, 2003) [PMID:12887265]
- Emtricitabine/tenofovir disoproxil fumarate. (Drugs R D, 2004) [PMID:15139777]
_Worker-drafted node — pending editorial review._
Connections
tenofovir disoproxil is a side effect of
Sources
- Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. (2020) pubmed
- Emtricitabine/tenofovir disoproxil fumarate. (2004) pubmed
- Tenofovir disoproxil fumarate. (2003) pubmed
- Tenofovir disoproxil fumarate. (2003) pubmed
- Is tenofovir disoproxil fumarate associated with weight loss? (2021) pubmed
- Tenofovir disoproxil fumarate therapy to prevent hepatitis B virus vertical transmission-A review of maternal and infant outcomes. (2022) pubmed
- Neuropsychiatric adverse events in tenofovir disoproxil fumarate- and tenofovir alafenamide-based HIV therapy and prophylaxis: a systematic review and meta‑analysis. (2024) pubmed
- Tenofovir disoproxil fumarate for prevention of mother-to-child transmission of hepatitis B virus: A systematic review and meta-analysis of randomised control trials. (2021) pubmed
- Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B infection. (2010) pubmed
- Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. (2004) pubmed